| Name | Title | Contact Details |
|---|
Since 1972, GMCF has been providing medical peer review and consultative services, utilization and quality management review services for Medicaid Programs.
Aid in Recovery is a addiction treatment center referral service.
Privis Health is a leading provider of innovative data-driven population health programs and technology rich services that enable healthcare providers to deliver high quality efficient care to their patient population. Our scalable, cloud-based platform empowers healthcare providers to better manage risk, while achieving their operating and performance goals as they transition from fee-for-service to value based reimbursement. In addition, we assist with the design, implementation and expansion of population health programs, while sharing in the accountability for the success of these initiatives. The Privis team has deep experience with a programmatic approach to provide strategies on service models, organizational transformation, quality improvements and learning health system activities. Offerings include care management, care coordination, transitions of care, chronic care management, and complex CCM programs working in tandem with patient engagement and placement services. We provide a tool kit of evidence-based chronic disease and socio-behavioral assessments that drive the creation of a dynamic shared care plan. Our gaps-in-care offering captures important variances in care, such as preventive care, community resources, and guides interventions to assist the patient in achieving better outcomes and appropriate interventions
4x Award Winner WHETHER YOU HAVE AN EXISTING BRAND OR ARE LOOKING TO START UP A NEW LINE, FORMULIFE SUPPLEMENTS HAS THE EXPERIENCE AND FACILITY TO ASSIST YOUR BUSINESS EVERY STEP OF THE WAY.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.